製品番号: HY-N0809

セサモリン

(別名: Sesamolin)

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Sesamolin, isolated from Sesamum indicum, has antioxidative activity, Sesamolin inhibits lipid peroxidation and shows neuroprotection effect. Sesamolinl potently inhibits MAPK cascades by preventing phosphorylation of JNK, p38 MAPKs, and caspase-3 but not ERK-MAPK expression. Sesamolin is orally active.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.51%
CAS 番号: 526-07-8
分子式: C₂₀H₁₈O₇
分子量:370.35

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Sesamolin 構造式

CAS 番号: 526-07-8

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

p38 MAPK アイソフォーム固有の製品をすべて表示 :

JNK アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

体外実験

Sesamolin (0.5-50 μM, 1-2 h) reduces the release of LDH and ROS generation in H₂O₂ or hypoxia-stimulated PC12 cell, increases the cell viability, and exhibits antioxidant activity.
Sesamolin (0-10 μM, 5 days) inhibits RANKL-induced formation and differentiation of osteoclast in bone marrow macrophages, inhibits the bone resorption of osteoclasts through inhibition of NF-κB/MAPK signaling pathway, and suppression of c-Fos and NFATc1 expressions^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:

PC12
Concentration:

0.5-50 μM
Incubation Time:

1-2 h
Result:

Increased H₂O₂ or hypoxia-inhibited cell viability.

Western Blot Analysis

Cell Line:

bone marrow macrophages
Concentration:

10 μM
Incubation Time:

5 days
Result:

Inhibited levels of c-Fos and NFATc1.

体内実験

Sesamolin (5 mg/kg, ip, every two days for 42 days) reduces the bone loss in mouse OVX-induced osteoporosis models^[5].
Sesamolin (60 mg/kg, po, twice a day for 3 weeks) improves metabolic disorders, attenuates hepatic steatosis, alleviates endotoxemia and systemic inflammation, alters the composition of gut microbiota, changes serum metabolites and metabolomics pathways, thereby ameliorating high-fat and high-fructose diet -induced non-alcoholic fatty liver disease in mouse models^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mouse OVX-induced osteoporosis models^[5]
Dosage:

5 mg/kg
Administration:

ip, every two days for 42 days
Result:

Reduced the bone loss and increased trabecular parameters.

Animal Model:

High-fat and high-fructose diet -induced non-alcoholic fatty liver disease (NAFLD) in mouse models^[6]
Dosage:

60 mg/kg
Administration:

po, twice a day for 3 weeks (from 9th week to 12th week)
Result:

Inhibited weight gain, reduced the liver weight.
Reduced serum levels of glucose, insulin, HOMA-IR, total cholesterol, HDL-C, LDL-C, endotoxin, LBP, IL-6, TNF-α, AST and ALT.
Altered the composition of the gut flora, increased the relative abundance of beneficial bacteria and decreased the relative abundance of harmful bacteria.

化学情報

CAS 番号 526-07-8
性状 Solid
分子量 370.35
分子式 C₂₀H₁₈O₇
Color White to off-white
SMILES

[H][C@@]12[C@@](CO[C@@H]2C3=CC(OCO4)=C4C=C3)([H])[C@H](OC1)OC5=CC(OCO6)=C6C=C5
別名

Sesamolin
Structure Classification
- Phenylpropanoids
- Other Phenylpropanoids
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All IFWB

Sort by:

Journal Impact Factor

Int Immunopharmacol

Hepatocyte-derived exosomes deliver H2AFJ to hepatic stellate cells and promote liver fibrosis via the MAPK/STMN1 axis activation. [Abstract]

2023 Feb:115:109605. PMID: 36608439

Sesamolin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Feb:115:109605. [Abstract]

Sesamolin inhibits exosomal H2AFJ-induced migration and invasion of HSCs, while simultaneous overexpression of STMN1 promotes HSC migration and invasion again.

Sesamolin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Feb:115:109605. [Abstract]

Both treatment with Sesamolin (5 μM; 24 h) and oe-STMN1 increases STMN1 expression in HSCs co-cultured with exosomes overexpressing H2AFJ in HSCs.
Heliyon

The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway. [Abstract]

2023 Apr 27;9(5):e15805. PMID: 37251857

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (270.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7001 mL

13.5007 mL

27.0015 mL

5 mM

0.5400 mL

2.7001 mL

5.4003 mL

10 mM

0.2700 mL

1.3501 mL

2.7001 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (6.75 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Dorothea Bedigian, et al. Sesamin, sesamolin and the origin of sesame. Biochemical Systematics and Ecology. Volume 13, Issue 2, 23 May 1985, Pages 133-139.

[2]. Myung-Hwa Kang, et al. Sesamolin Inhibits Lipid Peroxidation in Rat Liver and Kidney. The Journal of Nutrition, Volume 128, Issue 6, June 1998, Pages 1018–1022.

[3]. Rolis Chien‐Wei Hou, et al. Protective effects of sesamin and sesamolin on hypoxic neuronal and PC12 cells. [Content Brief]

[4]. Lim JS, et al. Comparative analysis of sesame lignans (sesamin and sesamolin) in affecting hepatic fatty acid metabolism in rats. Br J Nutr. 2007 Jan;97(1):85-95. [Content Brief]

[5]. Yang X, et al., Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways. Front Pharmacol. 2021 Jun 14;12:664697. [Content Brief]

[6]. Yu J, et al., Sesamolin Alleviates Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites in High-Fat and High-Fructose Diet-Fed Mice. Int J Mol Sci. 2022 Nov 10;23(22):13853. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7001 mL	13.5007 mL	27.0015 mL	67.5037 mL
	5 mM	0.5400 mL	2.7001 mL	5.4003 mL	13.5007 mL
	10 mM	0.2700 mL	1.3501 mL	2.7001 mL	6.7504 mL
	15 mM	0.1800 mL	0.9000 mL	1.8001 mL	4.5002 mL
	20 mM	0.1350 mL	0.6750 mL	1.3501 mL	3.3752 mL
	25 mM	0.1080 mL	0.5400 mL	1.0801 mL	2.7001 mL
	30 mM	0.0900 mL	0.4500 mL	0.9000 mL	2.2501 mL
	40 mM	0.0675 mL	0.3375 mL	0.6750 mL	1.6876 mL
	50 mM	0.0540 mL	0.2700 mL	0.5400 mL	1.3501 mL
	60 mM	0.0450 mL	0.2250 mL	0.4500 mL	1.1251 mL
	80 mM	0.0338 mL	0.1688 mL	0.3375 mL	0.8438 mL
	100 mM	0.0270 mL	0.1350 mL	0.2700 mL	0.6750 mL

Keywords

Sesamolin

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

セサモリン

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Sesamolin

p38 MAPK アイソフォーム固有の製品をすべて表示

JNK アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

NF-κB アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)